Silver Book Fact

Lucentis to treat wet age-related macular degeneration (AMD)

An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25% to 34% of trial participants.

Rosenfeld P, Brown D, Heier J, Boyer D, et al. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2006; 355(14): 1419-31. http://content.nejm.org/cgi/content/abstract/355/14/1419

Reference

Title
Ranibizumab for Neovascular Age-Related Macular Degeneration
Publication
N Engl J Med
Publication Date
2006
Authors
Rosenfeld P, Brown D, Heier J, Boyer D, et al
Volume & Issue
Volume 355, Issue 14
Pages
1419-31
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • It is estimated that proper treatment and monitoring of the eyes of diabetics could reduce new cases of diabetic retinopathy by 90%.  
  • Between 2008 and 2009, the number of Americans age 65-74 who reported trouble seeing (even with glasses or contacts) decreased from 14.3% to 10.3%.  The number of Americans age 75…  
  • The ACCORD Eye Study found that intensive glycemia control–compared with standard blood sugar control–in high risk type 2 diabetics, decreased progression of diabetic retinopathy by around 1/3 over 4 years–from…  
  • The use of antioxidant vitamins and other new therapies for age-related macular degeneration (AMD) could reduce visual impairment and blindness from the disease by 35%.  
  • Current treatments for proliferative diabetic retinopathy have reduced the rate of blindness within 5 years from 50% to less than 5%.